Improving how CAR T cells are timed for lymphoma outcomes
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 trial tests a method to better time “cell therapy” (CAR T) called Yescarta in people with relapsed or refractory large B-cell lymphoma. The goal is to improve outcomes by optimizing how the body is prepared before CAR T treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older when you sign consent
- You have lymphoma confirmed by biopsy, and it is one of the listed types of large B-cell lymphoma
- Your scans show measurable, active lymphoma lesions (PET-avid and large enough)
- You are a good candidate for standard CAR T for large B-cell lymphoma and you’ve had at least two prior treatment lines, including anti-CD20 treatment and an anthracycline chemotherapy
- You have no active cancer in the brain or spinal fluid (CNS)
- You are well enough to safely receive CAR T (stable health, not needing intensive life-support), and your functional status is 0–1
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests a personalized immune-cell treatment (CAR-T) called C-CAR039 for adults with certain types of large B-cell lymphoma that has come back or did not respond to treatment. It may help by attaching to lymphoma cells and training your immune system to fight them.
This study looks at how the standard chemotherapy given before CAR T-cell therapy affects the treatment's success in people with large B-cell lymphoma that has come back or not responded to previous treatment. It may help doctors find the best way to prepare your body for CAR T-cells.
This trial studies a type of immune therapy (CAR T-cells) for people whose leukemia or lymphoma has come back or did not respond after at least two treatment attempts. It aims to improve outcomes in carefully selected patients who can safely receive the treatment.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.